Jump to content


Do you want up to date information about Scleroderma? Check out our Medical pages at www.sclero.org for all your Scleroderma questions!


Surface Logix Commences Phase 2a Clinical Trial Of Slx-2101 In Raynaud's Disease


  • Please log in to reply
No replies to this topic

#1 Guest_Jude the Grouch_*

Guest_Jude the Grouch_*
  • Guests

Posted 06 July 2007 - 07:46 AM

Surface Logix Commences Phase 2a Clinical Trial of SLx-2101 in Raynaud's Disease. SLx-2101 is a novel, long-acting PDE-5 inhibitor being developed for the management of diseases associated with vascular dysfunction such as Raynaud's. Digital50. Surface Logix Inc. 06/28/07. (Also see: Raynaud's Treatments, and Clinical Trials)